DelveInsight Business Research LLP

DelveInsight’s “Macular Telangiectasia Market Insights, Epidemiology, and Market Forecast-2032″ report delivers an in-depth understanding of the Macular Telangiectasia, historical and forecasted epidemiology as well as the Macular Telangiectasia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Macular Telangiectasia market report provides current treatment practices, emerging drugs, Macular Telangiectasia market share of the individual therapies, current and forecasted Macular Telangiectasia market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Macular Telangiectasia treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Macular Telangiectasia market.

Some of the key facts of the Macular Telangiectasia Market:

• In a study conducted by Maruko et al. (2012), thirty-four eyes of 27 patients with MacTel were included. Twenty eyes of 20 patients (74.1%) had type 1, ten eyes of five patients (18.5%) had type 2, and four eyes of two patients (7.4%) had type 3. The most frequent type of MacTel in Japan was found to be the aneurysmal type, whereas the perifoveal type was not common. Clinical characteristics were similar to those of patients in Western countries; however, the most frequent type was different. 

• As per Cirafici et al. (2021), Idiopathic macular telangiectasia type 1 (MacTel 1) is a rare unilateral and predominantly affecting male ocular pathology 

Got queries? Click here to know more about the Macular Telangiectasia Market Landscape 

Macular Telangiectasia Overview 

Macular telangiectasia (MacTel) is a disease that affects the macula, causing central vision loss. It’s caused by abnormal blood vessels around the fovea. The fovea is centre of the macula and is used for detailed central vision. There are two main types of macular telangiectasia – type 1 and type 2. The blood vessel changes are different in each type. Additionally, Idiopathic juxtafoveal retinal telangiectasia type 3 is a rare, poorly understood disease characterized by a bilateral, severe, occlusive vasculopathy affecting the macula, often associated with systemic disease.

Signs of macular telangiectasia can be detected during a comprehensive eye examination by your optometrist or ophthalmologist. Your eye health professional may do further tests such as optical coherence tomography (OCT) and fluorescein angiography (FA) to confirm the diagnosis. Unfortunately, there’s currently no effective treatment for macular telangiectasia. In cases where new blood vessels have formed under the retina, health professionals suggest injections of anti-vascular endothelial growth factor (VEGF) into the eye to help prevent further vision loss. No recent development has been reported in this space for the disease macular Telangiectasia, although previously some major companies have tried to evaluate the role of emerging implants in treatment such as Neurotech Pharmaceuticals.

Macular Telangiectasia Epidemiological Insight:

• According to Klein et al. (2010), as per the Beaver Dam Eye Study in the US, macular telangiectasia type 2 (MacTel 2) was present in 0.1% of the predominantly white Beaver Dam Eye Study cohort 43–86 years of age. Based on the US white population this age, it was estimated that there were approximately 70,000 people with this condition.

• According to Christakis et al. (2019), macular telangiectasia usually begins to affect patients between the ages of 40 and 60 years. The prevalence of macular telangiectasia is estimated to be 0.022% to 0.1%, based on an assessment of fundus photographs from large population-based studies.

• As per the study conducted by Porras et al. (2017) in Spain, MacTel 2  is a rare retinal disease that has still not been well-defined. In accordance with the registry comprising all 4903 patients visited by the same specialist (RGP) of the Macula Unit of the University and Polytechnic Hospital of La Fe, Valencia, Spain, between January 2013 and May 2017, the estimated prevalence was found to be 0.12%.

Macular Telangiectasia Epidemiological Segmentation

• Macular Telangiectasia prevelant cases

• Macular Telangiectasia diagnosed cases 

• Macular Telangiectasia type-specific cases 

• Macular Telangiectasia treated cases 

Macular Telangiectasia Market Outlook 

The Macular Telangiectasia market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted Macular Telangiectasia market trends by analyzing the impact of current Macular Telangiectasia therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of the Macular Telangiectasia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Macular Telangiectasia market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Macular Telangiectasia market in 7MM is expected to witness a major change in the study period 2019-2032.

 Learn more by requesting for sample @Macular Telangiectasia Market Landscape

Macular Telangiectasia Key Companies 

• Neurotech Pharmaceuticals

• And others 

 Macular Telangiectasia Key Therapies

• Renexus (NT-501)

• And others 

Table of Contents

1. Key Insights 

2. Report Introduction 

3. Executive Summary of Macular Telangiectasia Market 

4. Disease Background and Overview

5. Epidemiology and patient population

6. The United States 

7. EU 5

8. Macular Telangiectasia Market  Emerging Therapies

9. Macular Telangiectasia Market Outlook

10.  Market Access and Reimbursement of Therapies

11.  Appendix

12. Macular Telangiectasia Market Report Methodology

13. DelveInsight Capabilities

14. Disclaimer

15. About DelveInsight

Click here to read more about Macular Telangiectasia Market

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Adya Kaul
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432, Las Vegas NV
City: Las Vegas
State: United States
Country: United States
Website: https://www.delveinsight.com